Impact of Adjuvant Androgen-Deprivation Therapy on Disease Progression in Patients with Node-Positive Prostate Cancer.
10.4111/kju.2011.52.11.741
- Author:
Sejun PARK
1
;
Seong Cheol KIM
;
Wansuk KIM
;
Cheryn SONG
;
Hanjong AHN
Author Information
1. Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. hjahn@amc.seoul.kr
- Publication Type:Original Article
- Keywords:
Androgens;
Lymph nodes;
Prostatectomy
- MeSH:
Androgens;
Cohort Studies;
Disease Progression;
Disease-Free Survival;
Humans;
Lymph Nodes;
Neoplasm Metastasis;
Prostate;
Prostatectomy;
Prostatic Neoplasms;
Recurrence;
Salvage Therapy
- From:Korean Journal of Urology
2011;52(11):741-745
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: The survival benefits of adjuvant androgen-deprivation therapy (ADT) in prostate cancer and lymph node metastasis remain unclear. We assessed the role of ADT in disease progression after radical prostatectomy (RP). MATERIALS AND METHODS: Of 937 patients who underwent RP, we identified 40 (4.2%) who had lymph node metastasis. A total of 18 received adjuvant ADT (ADT group) and 22 were observed (observation group). Clinical progression-free survival (PFS), cancer- specific survival (CSS), and overall survival (OS) were compared in the 2 groups. Prognostic factors for clinical progression and biochemical recurrence (BCR) were analyzed. RESULTS: The 5-year PFS, CSS, and OS of the entire cohort were 75.0%, 85.0%, and 72.5%, respectively. In the ADT group, 6 patients (33.3%) showed clinical progression at a median 42.7 months. The 5-year PFS, CSS, and OS rates of this group were 72.2%, 83.3%, and 72.2%, respectively. In the observation group, 14 patients (63.6%) received salvage therapy owing to BCR. Nine patients (40.9%) with BCR in the observation group showed clinical progression at a median 43.4 months after RP. The 5-year PFS, CSS, and OS rates of this group were 77.2%, 86.4%, and 72.8%, respectively. In the observation group, the BCR rate was lower in patients with pT3a or less disease than in those with pT3b disease. CONCLUSIONS: Adjuvant ADT in node-positive prostate cancer did not reduce or delay disease progression or improve survival. Because a substantial number of untreated patients with pT3a or less disease did not experience recurrence, administration of ADT should be initiated carefully. However, in patients with pT3b disease, adjuvant ADT and radiotherapy could be considered.
